Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication ...

Eli Lilly stock (NYSE: LLY) is up 7% in a month, warranting investor attention following a key corporate development. Eli ...

Eli Lilly said on Wednesday it is partnering with Walmart to sell its weight-loss treatment Zepbound at the retailer's ...

Eli Lilly said on Wednesday it is partnering with Walmart to expand access to Lilly's weight-loss drug Zepbound, which will ...

The deal, which enables patients to pick up orders placed through Lilly’s online channel at Walmart pharmacies, is the latest ...

November, cash-paying patients can purchase Zepbound vials at discounts of 50% or more through the retailer's locations or ...

On Wednesday, Lilly said Zepbound would be sold directly in Walmart pharmacies for $349 to $499 a month. Next year, Lilly is ...

Eli Lilly (LLY) stock rises after reporting that sales of its weight-loss drugs more than doubled in the third quarter. The ...

Revenue from Mounjaro, the company’s Type 2 diabetes treatment, came in at $6.5 billion, above analysts’ consensus estimate ...

Eli Lilly (LLY) and Walmart (WMT) announced a partnership to expand access to Zepbound (tirzepatide) through LillyDirect’s ...

Pharma giant Eli Lilly tapped Walmart to offer in-store pickups of Zepbound vials, marking the first retail collaboration for ...

The partnership between LillyDirect and Walmart allows patients to pick up Zepbound at Walmart pharmacies at the same self-pay price as online. Sel ...